Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 2, 1996, Pages 191-194

  Feliu, J ^a   Gonzalez Baron, M ^a   Chacon J I ^b   Espinosa, E ^a   Garrido, P ^c   Castro, J ^a   Escobar, Y ^d   Colmenarejo, A ^e   Jara, C ^f   Garcia Giron, C ^g   Espinosa, J ^g   Ordonez A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Hospital Provincial de Madrid   (Spain)

^e Hospital Militar del Aire   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^g Ruber International Hospital   (Spain)

Author keywords

chemotherapy; cisplatin; malignant melanoma; tamoxifen

Indexed keywords

CISPLATIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; TAMOXIFEN; TREATMENT OUTCOME;

EID: 9244244128     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050469     Document Type: Article

References (25)

1. Atkins MB, O'Bayle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, Eckardt JR, Pereira C, Aranson FR (1994) Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12: 1553
2. Bajetta E, Zampino MG, Nole F, Zilembo N (1993) Tamoxifen does not improve response when added to chemotherapy in metastatic melanoma. Italian Trials in Medical Oncology (ITMO) study. Proc Am Soc Clin Oncol 12: 1345
3. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Cedi G, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC, Bacchi M (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327: 516
4. Creagan ET, Ingle JN, Woods JE, Pritchard DJ, Jiang NA (1980) Estrogen receptors in patients with malignant melanoma. Cancer 46: 1785
5. Ferri W, Agarwala SS, Kikwood JM, Gooding W, Vlock D, Miketic L, Donnelly S (1994) Carhoplatin (C) and dacarbazine (D) +/- tamoxifen (T) for metastatic melanoma. Proc Am Soc Clin Oncol 13: 1341
6. Fisher RI, Neifield JP, Lippman ME (1976) Estrogen receptors in human malignant melanoma. Lancet II: 337
7. Fornander T, Hellström AC, Moberger B (1993) Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85: 1850
8. Glover D, Glick JH, Welser C, Fox K, Guerry D (1987) WR2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 5: 574
9. Goodnight JE Jr, Moseley HS, Eilber FR (1979) cis-Dichlorodiammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep 63: 2005
10. Ho RCS (1995) Medical management of stage IV malignant melanoma. Cancer 75: 735
11. Legha S (1989) Current therapy for malignant melanoma. Semin Oncol 16: 34
12. Legha S, Ring S, Bedikian A, Eton O, Plager C, Papadopoulos N, Ensign LG, Benjamin RS (1993) Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D) and alpha Interferon (IFN) in patients (PTS) with metastatic melanoma (MM). Proc Am Soc Clin Oncol 12: 1325
13. McClay EF, McClay ET (1994) Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12: 617
14. McClay EF, Albirght KD, Jones JA, Eastman A, Christen R, Howell SB (1992) Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52: 6790
15. McClay EF, Albright KA, Jones JA, Christen RD, Howell SB (1993) Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53: 1571
16. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB (1993) Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer 55: 1018
17. McClay EF, McClay MET, Albright KD, Jones JA, Christen RD, Alcaraz J, Howell SB (1993) Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation. Cancer 72: 1914
18. McClay EF, Aibright KD, Jones JA, Christen RD, Howell SB (1994) Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 70: 449
19. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB (1994) Tamoxifen (T)/cisplatin (DDP) synergy may be mediated via antiestrogen binding sites (AEBS). Proc Am Soc Clin Oncol 13: 1356
20. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 42: 207
21. Rümke P, Kleeberg UR, MacKie RM, Lejeune FJ, Planting AS, Brocker EB, Bierhorst JF, Lentz MA (1992) Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Melanoma Res 2: 153
22. Thompson DB, Walpole ET, Beadle GF, McLeod GR, Smithers BM (1993) High dose tamoxifen does not enhance the activity of dacarbazine in metastatic melanoma: QMP9105. Proc Am Soc Clin Oncol 12: 392
23. Verweij J, Clavel M, Chevalier B (1994) Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495
24. Zava DT, Goldhirsch A (1983) Estrogen receptor in malignant melanoma: fact or artefact? Eur J Cancer Clin Oncol 19: 1151
25. Zubrod C, Schneidernman M, Frei I (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and thiethylene thiophosphoramine. J Chronic Dis 11: 7